- authorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies
This study is testing a new drug (REGN10597) for cancers like melanoma and kidney cancer. It aims to see how safe it is, how well it's tolerated, and if it helps shrink tumours, either alone or with an existing treatment called Libtayo.
Italy · Spain · Germany - recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria